Novo Nordisk’s Dividend Story is Changing — Here’s What Investors are Missing
Novo Nordisk (NYSE: NVO) is a large drug maker that built its business around treating diabetes. That was how it got into the GLP-1 weight-loss drug space However, the opportunity for weight-loss drugs is much larger than the diabetes market. The company is working